

*We invite you to join your colleagues and
your Janssen Pharmaceuticals, Inc., Sales Representative for*

INVOKANA[®]:
**An Individualized Approach to the
Treatment of Adults with Type 2 Diabetes**

OUR GUEST SPEAKER WILL BE

Robert Busch, MD

Managing Partner, The Endocrine Group
Albany, NY

Dr. Busch is a paid speaker for Janssen Pharmaceuticals, Inc.

Wednesday, June 10, 2015 at 6:30 PM

Cena 2000

50 Front St Ste 100, Newburgh, NY 12550

Phone: (845) 561-7676

Please RSVP to your Janssen Representative by Wednesday, June 03, 2015

William Rall Jr

Phone: (845) 527-0306 or visit <http://www.medforcereg.net/SOMP72993>

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

This promotional educational activity is not accredited. The program content is developed by Janssen Pharmaceuticals, Inc. Speakers present on behalf of the company and are required to present information in compliance with FDA requirements for communications about its medicines.

The personal information you provide may be used to contact you about your request to attend the Janssen Pharmaceuticals, Inc. educational program using your preferred method of communication as indicated by you. This information may be shared with Janssen Pharmaceuticals, Inc., its affiliates, and a third party for the sole purpose of completing your registration for this program and as required by law.

INVOKANA[®] (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

INVOKANA[®] is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

- History of a serious hypersensitivity reaction to INVOKANA[®]
- Severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis

Please see accompanying Full Prescribing Information

Please see Important Safety Information continued on next page.

Janssen Pharmaceuticals, Inc.

Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation.
© Janssen Pharmaceuticals, Inc. 2014 August 2014 003998-140807